Evidence map›Paper›PMID 38520063›Full record

ArticleUnited European gastroenterology journal2024

A regular screening for hepatitis delta virus among chronic hepatitis B carriers improves the diagnostic of this infection and of subsequent cirrhosis development.

Laura Weichselbaum, Hassane Njimi, Sigi van den Wijngaert, Hafid Dahma, Marcel Nkuize, Marc Van Gossum, Pierre Eisendrath, Jean-Pierre Mulkay, Thomas Sersté

Open access · hybridAbstract read
In one paragraph

Article in United European gastroenterology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Laura WeichselbaumDepartment of Gastroenterology and Hepatology, CHU Saint-Pierre, Brussels, Belgium.ORCID 0000-0001-8869-944X
Hassane NjimiDepartment of Intensive Care, CUB Erasme, Brussels, Belgium.
Sigi van den WijngaertDepartment of Microbiology, LHUB-ULB site Porte de Hal, Brussels, Belgium.
Hafid DahmaDepartment of Microbiology, LHUB-ULB site Porte de Hal, Brussels, Belgium.
Marcel NkuizeDepartment of Gastroenterology and Hepatology, CHU Saint-Pierre, Brussels, Belgium.
Marc Van GossumDepartment of Gastroenterology and Hepatology, CHU Saint-Pierre, Brussels, Belgium.
Pierre EisendrathDepartment of Gastroenterology and Hepatology, CHU Saint-Pierre, Brussels, Belgium.
Jean-Pierre MulkayDepartment of Gastroenterology and Hepatology, CHU Saint-Pierre, Brussels, Belgium.
Thomas SerstéDepartment of Gastroenterology and Hepatology, CHU Saint-Pierre, Brussels, Belgium.
Erasmus Hospital · BECentre Hospitalier Universitaire de Saint-Pierre · BEDirectorate-General Joint Research Centre · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe prevalence of Hepatitis Delta Virus (HDV) is underestimated and the assessment of fibrosis is recommended for this infection. We tested the diagnostic impact of an annual screening for HDV serology in Hepatitis B Surface Antigen (HBs Ag) chronic carriers and followed the progression of fibrosis in these patients.

methodsBetween January 2014 and October 2021, we annually tested all chronic HBs Ag-positive patients for HDV antibody (HDV Ab). Each HDV Ab positive patient underwent annually repeated elastometry. Patients with detectable HDV RNA levels (group 1) were compared to those with undetectable HDV RNA (group 2).

resultsWe identified 610 chronic HBs Ag-positive patients, and repeated screening for HDV Ab was performed in 534 patients. Sixty (11%) patients were HDV Ab positive at baseline and were considered as "coinfected". Seven cases of HDV superinfection were diagnosed through repeated screening. In co-infected patients, cirrhosis was initially diagnosed in 12/60 patients and developed in six patients during follow-up. HDV RNA PCR was performed in 57/67 patients and 27 had detectable levels (group 1). Cumulative incidence of cirrhosis at 7 years was 13.8% (95% CI 0-30) in group 1 and 0 (95% CI 0-0) in group 2 (p = 0.026).

conclusionA systematic screening for HDV in chronic HB Ag carriers revealed a high prevalence of HDV Ab. Repeated serological screening enables the diagnosis of superinfections in asymptomatic patients. Regular assessment of fibrosis using elastometry leads to the identification of incidental cirrhosis in patients with detectable HDV RNA.

Indexed as

Carrier StateHepatitis B, ChronicHepatitis B Surface AntigensHepatitis DHepatitis Delta VirusLiver CirrhosisMass ScreeningAdultAgedCoinfectionDisease ProgressionElasticity Imaging TechniquesFemaleHepatitis AntibodiesHumansIncidenceHepatitis AntibodiesHepatitis B Surface AntigensRNA, ViralantibodiesdiagnosiselastographyepidemiologyfibroscanHBVhepatitis Dviremiavirus

Identifiers

PMID38520063
PMCPMC11091775
OpenAlexW4393118318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.